PF4 and COVID-19: Heightened clinical suspicion and testing for PF4 antibodies in patients with unexplained thrombosis and thrombocytopenia, combined with the simultaneous administration of billions of rAV-based COVID-19 vaccines, may have led to a skewed impression that rAV-based vaccines are uniquely associated with VITT.